Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,605.62
(
1.52%
)
US TECH 100
23,621.20
(
1.46%
)
Dow Jones
46,377.10
(
1.75%
)
Brent Oil
95.85
(
-11.36%
)
Bitcoin
70,880.00
(
4.48%
)
News Focus
News Focus
Post# of 257272
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: p3analyze post# 90332

Thursday, 12/09/2010 7:37:32 PM

Thursday, December 09, 2010 7:37:32 PM

Post# of 257272
Zometa fails to extend DFS in adjuvant breast-cancer trial that tested (chemo)+(aromatase inhibitor) ± Zometa:

http://www.reuters.com/article/idUS185738+09-Dec-2010+HUG20101209?feedType=RSS&feedName=huginPressRelease&rpc=43

The failure is not a big deal financially for NVS because Zometa goes off-patent in major countries in about two years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today